There are 2789 resources available
618P - Apalutamide (APA) for advanced prostate cancer in older patients (pts): Combined analysis of TITAN & SPARTAN
Presenter: John Shen
Session: ePoster Display
680P - Cabozantinib and axitinib after VEGF therapy in patients with aRCC: A retrospective cohort study
Presenter: Janet Brown
Session: ePoster Display
600P - Final results of phase I/II trial of fractionated dose 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Scott Tagawa
Session: ePoster Display
663P - First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
Presenter: Camillo Guglielmo Porta
Session: ePoster Display
664P - Final results from phase I trial of cabozantinib/nivolumab (CaboNivo) alone or with ipilimumab (CaboNivoIpi) and peripheral immunity in metastatic genitourinary (mGU) tumors
Presenter: Andre Kydd
Session: ePoster Display
665P - Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101
Presenter: Marc-Oliver Grimm
Session: ePoster Display
666P - Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A
Presenter: David McDermott
Session: ePoster Display
667P - Cost effectiveness of immune checkpoint inhibitors in combination with targeted therapies in metastatic renal cell carcinoma
Presenter: Neil Mason
Session: ePoster Display
Resources:
Abstract
668P - Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
Presenter: Camillo Guglielmo Porta
Session: ePoster Display
669P - Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study
Presenter: Rustem Gafanov
Session: ePoster Display